CISBIO Announces FDA Approval of MESOMARK(R) Assay; Now Availabe to Physicians in the U.S. for Monitoring Patients with Mesothelioma

SACLAY, France--(BUSINESS WIRE)--CISBIO, a developer and marketer of diagnostic assays for the quantification of tumor markers, announced that the MESOMARK® Assay, the world’s first in vitro test for managing patients with mesothelioma, an aggressive and deadly form of cancer, has been approved by the United States Food and Drug Administration (FDA). The MESOMARK® test is developed and manufactured by Fujirebio Diagnostics, Inc. of Malvern, PA; CISBIO is the exclusive distributor of MESOMARK® in Europe, where it is currently undergoing evaluation for clinical use.

>>> Discuss This Story

Back to news